Allen L Cohn

Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article and Find Full Text PDF

May 2015

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.

Authors:

Axel Grothey E Dawn Flick Allen L Cohn Tanios S Bekaii-Saab Johanna C Bendell Mark Kozloff Nancy Roach Yong Mun Susan Fish Herbert I Hurwitz

Pharmacoepidemiol Drug Saf 2014 Jul 16;23(7):726-34. Epub 2014 May 16.

Mayo Clinic, Medical Oncology, Rochester, MN, USA.

View Article and Find Full Text PDF

July 2014

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.

Authors:

Charles S Fuchs Marwan Fakih Lee Schwartzberg Allen L Cohn Lorrin Yee Luke Dreisbach Mark F Kozloff Yong-jiang Hei Francesco Galimi Yang Pan Vincent Haddad Cheng-Pang Hsu Antony Sabin Leonard Saltz

Cancer 2013 Dec 1;119(24):4290-8. Epub 2013 Oct 1.

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF

December 2013

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.

Authors:

Jeffrey R Infante Tony R Reid Allen L Cohn William J Edenfield Terrence P Cescon John T Hamm Imtiaz A Malik Thomas A Rado Philip J McGee Donald A Richards Jamal Tarazi Brad Rosbrook Sinil Kim Thomas H Cartwright

Cancer 2013 07 19;119(14):2555-63. Epub 2013 Apr 19.

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, USA.

View Article and Find Full Text PDF

July 2013

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.

Authors:

Johanna C Bendell Tanios S Bekaii-Saab Allen L Cohn Herbert I Hurwitz Mark Kozloff Haluk Tezcan Nancy Roach Yong Mun Susan Fish E Dawn Flick Darshan Dalal Axel Grothey

Oncologist 2012 26;17(12):1486-95. Epub 2012 Sep 26.

GI Oncology Research and Drug Development Unit, Sarah Cannon Research Institute, 250 25th Avenue N, Suite 100, Nashville, Tennessee 37203, USA.

View Article and Find Full Text PDF

June 2013

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Authors:

Allen L Cohn Grace C Shumaker Pankaj Khandelwal David A Smith Marcus A Neubauer Nilesh Mehta Donald Richards David L Watkins Kathy Zhang Mohamed R Yassine

Clin Colorectal Cancer 2011 Sep 28;10(3):171-7. Epub 2011 Apr 28.

Rocky Mountain Cancer Center, Denver, CO, USA.

View Article and Find Full Text PDF

September 2011

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Authors:

Roger M Lyons Thomas M Cosgriff Sanjiv S Modi Robert H Gersh John D Hainsworth Allen L Cohn Heidi J McIntyre Indra J Fernando Jay T Backstrom C L Beach

J Clin Oncol 2009 Apr 2;27(11):1850-6. Epub 2009 Mar 2.

Cancer Care Centers of South Texas and US Oncology, San Antonio, TX 78229, USA.

View Article and Find Full Text PDF

April 2009

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Authors:

Howard S Hochster Lowell L Hart Ramesh K Ramanathan Barrett H Childs John D Hainsworth Allen L Cohn Lucas Wong Louis Fehrenbacher Yousif Abubakr M Wasif Saif Lee Schwartzberg Eric Hedrick

J Clin Oncol 2008 Jul;26(21):3523-9

New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA.

View Article and Find Full Text PDF

July 2008

External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.

Authors:

Deborah T Blumenthal Cathryn Rankin Harmon J Eyre Robert B Livingston Alexander M Spence Keith J Stelzer Elisabeth J Rushing Mitchel S Berger Saul E Rivkin Allen L Cohn Stephen H Petersdorf

Cancer 2008 Aug;113(3):559-65

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah Health Sciences Center, Salt Lake City, Utah, USA.

View Article and Find Full Text PDF

August 2008